<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264041</url>
  </required_header>
  <id_info>
    <org_study_id>503.213</org_study_id>
    <nct_id>NCT02264041</nct_id>
  </id_info>
  <brief_title>Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine</brief_title>
  <official_title>The Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine (an Open-label, Randomised, Single-dose, Two-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the effect of cytochrome P 450 3A4 inhibition by itraconazole on the
      single dose pharmacokinetics of cilobradine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 56 hours after administration of Cilobradine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to 56 hours after administration of Cilobradine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>up to 56 hours after administration of Cilobradine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to Cmax (Tmax)</measure>
    <time_frame>up to 56 hours after administration of Cilobradine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant in plasma (λz)</measure>
    <time_frame>up to 56 hours after administration of Cilobradine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>up to 56 hours after administration of Cilobradine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body after p.o. administration (MRTpo)</measure>
    <time_frame>up to 56 hours after administration of Cilobradine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)</measure>
    <time_frame>up to 56 hours after administration of Cilobradine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)</measure>
    <time_frame>up to 56 hours after administration of Cilobradine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of parent compound excreted in urine with zero to 72 h in % of dose (fe0-tz)</measure>
    <time_frame>up to 72 hours after administration of Cilobradine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of cilobradine (CLR,0-tz)</measure>
    <time_frame>up to 72 hours after administration of Cilobradine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 46 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of visual phenomena</measure>
    <time_frame>up to 46 days</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically relevant findings in vital signs</measure>
    <time_frame>up to 32 days</time_frame>
    <description>blood pressure, pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically relevant findings in laboratory tests</measure>
    <time_frame>up to 32 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically relevant findings in 12-lead electrocardiogram</measure>
    <time_frame>up to 32 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>within 8 days after last PK sampling</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cilobradine, low dose plus itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilobradine, low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilobradine, high dose plus itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>main study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cilobradine, high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>main study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilobradine, low dose</intervention_name>
    <arm_group_label>Cilobradine, low dose plus itraconazole</arm_group_label>
    <arm_group_label>Cilobradine, low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilobradine, high dose</intervention_name>
    <arm_group_label>Cilobradine, high dose plus itraconazole</arm_group_label>
    <arm_group_label>Cilobradine, high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <arm_group_label>Cilobradine, low dose plus itraconazole</arm_group_label>
    <arm_group_label>Cilobradine, high dose plus itraconazole</arm_group_label>
    <other_name>Sempera®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males according to the following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             (BP, PR), 12-lead ECG, clinical laboratory tests

             1.1 No finding deviating from normal and of clinical relevance

             1.2 No evidence of a clinically relevant concomitant disease

          2. Age ≥21 and Age ≤55 years

          3. BMI ≥18.5 and BMI &lt; 30 kg/m2 (Body Mass Index)

          4. Resting pulse rate (PR; after 10 min. in the supine position) of more than 55 bpm

          5. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation

        Exclusion Criteria:

          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, ophthalmological, or hormonal disorders

          2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          3. History of relevant orthostatic hypotension, fainting spells or blackouts.

          4. Chronic or relevant acute infections

          5. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          6. Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          7. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial.

          8. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          9. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)

         10. Inability to refrain from smoking on trial days

         11. Alcohol abuse (more than 60 g/day)

         12. Drug abuse

         13. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         14. Excessive physical activities (within one week prior to administration or during the
             trial)

         15. Any laboratory value outside the reference range that is of clinical relevance
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>October 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

